H ave you ever watched a patient activate a metered-dose inhaler (MDI) that contains chlorofluorocarbon (CFC) and wondered if it just impacted the ozone layer and your risk of skin cancer? If not, others have. Over the past few years, the pharmaceutical industry has been developing alternative propellants for use in the MDI or dry-powder inhalation devices in order to comply with the international agreement entitled "Montreal Protocol on Substances that Deplete the Ozone Layer" and the US Clean Air Act. These agreements called for the phaseout of the CFCs and other ozone-destroying substances (ODS), and the virtual end of production and use by January 1996 in the US and other industrialized countries. Since 1996, CFCs were allowed for essential medical uses until adequate alternative chemicals or devices could be found and established as safe and effective. The FDA developed a list of drug prod-ucts (eg, albuterol, fluticasone, flunisolide, cromolyn, nedocromil, ipratropium, and atropine) that were classified as being exempt to these agreements, because the use of the ODS in their formulation was considered essential. That list will soon (in regulatory terms) have one less agent, the FDA has announced its final ruling that albuterol MDIs will no longer be included on the CFC's "essential use" list. This ruling was published in the Federal Register on March 31, 2005 and requires that production and sale of single ingredient albuterol CFC MDIs must stop by December 31, 2008.
Before the FDA was able to make this ruling, the following criteria had to be met: • sufficient non-ODS alternatives are available with the same indications and approximate level of convenience; • there are adequate post-marketing data for the alternative products; • supplies are adequate to meet the demand; • patients who require the product are adequately served; and • Health and Human Services/ FDA initiated notice of the proposed ruling and received public comments.
The FDA has now satisfied all of these requirements, and albuterol will be removed from the "essential use" list for CFCs. The pharmaceutical industry and the FDA should be congratulated for this accomplishment.
Maybe fluticasone propionate can be the next agent removed from this list since GlaxoSmithKline has announced it will be replacing Flovent Inhalation Aerosol with Flovent HFA Inhalation Aerosol, which uses hydrofluoroalkane (HFA-134a) instead of a CFC. We can only hope that the pharmaceutical industry continues to decrease the number of agents included on the "essential use" list in order that this threat to the ozone layer and our environment may be removed.
